Baupost Group - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baupost Group ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$64,028
-16.6%
7,419,2260.0%1.23%
-10.2%
Q2 2023$76,789
-32.1%
7,419,226
-28.8%
1.37%
-29.2%
Q1 2023$113,049
-11.8%
10,419,226
-8.8%
1.93%
-7.5%
Q4 2022$128,124
-99.9%
11,419,226
-14.9%
2.09%
-11.0%
Q3 2022$136,071,000
+11.9%
13,419,2260.0%2.35%
+30.8%
Q2 2022$121,578,000
-6.8%
13,419,226
-1.6%
1.80%
+28.1%
Q1 2022$130,430,000
-13.6%
13,643,333
-0.1%
1.40%
-5.9%
Q4 2021$150,945,000
+49.3%
13,660,1680.0%1.49%
+60.4%
Q3 2021$101,085,000
-29.8%
13,660,168
+37.8%
0.93%
-20.4%
Q2 2021$143,896,000
-19.3%
9,910,168
+13.5%
1.17%
-17.8%
Q1 2021$178,285,000
+14.9%
8,735,1680.0%1.42%
-0.8%
Q4 2020$155,224,000
+20.2%
8,735,1680.0%1.43%
+2.6%
Q3 2020$129,149,000
-33.9%
8,735,168
-6.2%
1.40%
-42.8%
Q2 2020$195,399,000
-9.2%
9,309,1680.0%2.44%
-23.2%
Q1 2020$215,135,000
-10.7%
9,309,1680.0%3.18%
+19.3%
Q4 2019$241,014,000
+32.9%
9,309,1680.0%2.66%
+29.6%
Q3 2019$181,343,000
+19.3%
9,309,1680.0%2.05%
+49.3%
Q2 2019$152,019,000
-28.0%
9,309,1680.0%1.38%
-22.4%
Q1 2019$211,039,000
-11.4%
9,309,1680.0%1.77%
-14.2%
Q4 2018$238,222,000
-21.7%
9,309,1680.0%2.07%
-11.2%
Q3 2018$304,131,000
+44.0%
9,309,1680.0%2.33%
+26.2%
Q2 2018$211,132,000
-6.5%
9,309,1680.0%1.85%
-15.2%
Q1 2018$225,747,000
-13.1%
9,309,1680.0%2.18%
-15.2%
Q4 2017$259,633,000
-18.5%
9,309,1680.0%2.57%
-35.4%
Q3 2017$318,746,000
-13.7%
9,309,168
+0.4%
3.97%
-5.9%
Q2 2017$369,476,000
+8.2%
9,273,9910.0%4.22%
+5.0%
Q1 2017$341,468,000
+15.5%
9,273,9910.0%4.02%
+4.3%
Q4 2016$295,655,000
+11.0%
9,273,991
+26.2%
3.86%
+1.8%
Q3 2016$266,400,000
+59.7%
7,350,9910.0%3.79%
+67.2%
Q2 2016$166,794,000
+36.5%
7,350,991
+13.1%
2.26%
+28.3%
Q1 2016$122,219,000
+16.2%
6,500,991
+1.3%
1.76%
-7.5%
Q4 2015$105,224,000
+49.1%
6,420,0280.0%1.91%
+62.5%
Q3 2015$70,556,000
-15.6%
6,420,0280.0%1.18%
-15.6%
Q2 2015$83,589,000
-24.3%
6,420,028
+0.8%
1.39%
-24.9%
Q1 2015$110,460,000
+22.1%
6,366,577
+5.0%
1.86%
+4.5%
Q4 2014$90,434,000
-35.3%
6,061,2280.0%1.78%
-27.0%
Q3 2014$139,711,000
-27.7%
6,061,2280.0%2.43%
-22.7%
Q2 2014$193,232,0006,061,2283.15%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q1 2021
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$60,515,5108.59%
Irenic Capital Management LP 2,760,948$23,826,9816.76%
Newtyn Management, LLC 1,841,560$15,892,6633.92%
Weiss Asset Management LP 7,457,060$64,354,4283.81%
Park West Asset Management LLC 1,983,251$17,115,4561.57%
Baupost Group 7,419,226$64,0281.23%
Oasis Management Co Ltd. 953,254$8,226,5820.36%
Chescapmanager LLC 287,333$2,479,6840.32%
GSA CAPITAL PARTNERS LLP 325,985$2,8130.24%
Virtus ETF Advisers LLC 29,232$252,2720.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders